Younger age, lower baseline VA, and more injections were associated with higher VA gain at two years. The advent of electronic medical records (EMR) has facilitated the collection of large amounts of data in routine clinical practice and thus has the potential to make retrospective study populations more representative of real life. (13) (14) (15) (16) (17) (18) This is very much dependent, however, on the quality of data entry and the reliable follow-up of patients, and so these issues can remain problematic. advantages of this dataset include the ability to clean and validate data directly, the completeness due to the mandatory input of relevant fields including VA, the consistency of VA measurements in ETDRS letters, the lack of requirement to merge data from different sites and systems, the standardised treatment scheme following national guidelines, and the ability to directly access the raw imaging data from each study visit.
Conclusion
The aim of this study is to analyse one-and two-year VA outcomes, determine predictive factors of VA gain in treatment-naive eyes from the Moorfields AMD database, and to aid in scientific progress by making the de-personalised raw data from from our study openly available to the research community. (21, 23) 
METHODS

Data Collection:
Data for this retrospective, comparative, non-randomised cohort study were extracted from the data warehouse, the centralised storage for all EMR data, of Moorfields Eye Hospital. 
Outcome Measures:
The primary outcomes were mean change in VA 
Statistical Analysis:
The data were analysed using the statistics software R (https://www.r-project.org/; provided in the public domain by R Core team 2017 R Foundation for Statistical Computing, Vienna, Austria).
The ggplot2 package was used for plots. The eye was defined as unit of analysis. Descriptive statistics included mean +/-95% confidence interval (CI), and median, where appropriate.
Differences between groups were evaluated using Mann Whitney U test and Pearson ChiSquare. Regression analysis was performed to assess relationship of predictive factors and VA gains. A p value of < 0.05 was interpreted as statistically significant.
Patient and Public Involvement:
Patients and public were not involved in the study as this was a retrospective cohort study.
Data Sharing Statement:
De-personalised data for this study will be openly available from the Dryad Digital Repository https://doi.org/10.5061/dryad.97r9289. Depersonalisation was carried out through hash function anonymisation of patient identification numbers, replacement of appointment dates with follow-up days to baseline, and categorising extreme age groups into age categories.
Approval of adequate depersonalisation was obtained by Moorfields Information
Governance.
RESULTS
Patient Demographics:
The Of the 1162 patients not completing the two year follow-up date, 254 patients had died. LTFU occurred in 27% of eyes for two year follow-up. To address the potentially resulting survival bias of, one-year outcomes for the cohort not completing 2-year follow-up and the cohort completing the 2-year follow-up are shown.
Visual outcomes at one and two years
Mean VA gain at one and two years were +5.5±0. 5 
DISCUSSION
In this study, we show that patients treated with ranibizumab and/or aflibercept for neovascular AMD at Moorfields Eye Hospital achieve good visual outcomes, particularly those patients who present at an earlier age with better visual acuity, and who subsequently receive frequent intravitreal injections.
The Moorfields AMD Database is a large, consistent, and clean dataset of neovascular AMD treatment and visual outcomes, perhaps the largest single-center dataset of its kind worldwide. We have made this freely available to download with this manuscript in an effort to benefit the AMD research community. At a minimum this will allow for use of alternative statistical approaches and facilitate research reproducibility. (21) We also hope it will allow for the testing of new hypotheses and thus provide new insights into the treatment of this condition. (27) We have also developed systems so that the Moorfields AMD Database is automatically updated over time, with minimal need for manual cleaning of data.
Just under 1000 new cases of neovascular AMD present to Moorfields Eye Hospital on a yearly basis -this may be particularly useful as new therapeutics for AMD continue to be introduced. Additionally, we plan on releasing data for long-term follow-up of these (five years and beyond), as well as their associated raw imaging data (colour fundus photography and optical coherence tomography (OCT) imaging in every eye at every visit).
At one and two years, our results of mean VA gains confirm the existing evidence in real-life studies, e.g., the Fight Retinal Blindness (FRB) group in Australia/New Zealand for ranibizumab/aflibercept with nearly identical baseline characteristics and visual acuity outcomes for mixed ranibizumab/aflibercept treatment ( 2 ). The extensive manual cleaning and the homogeneous standards of data input (VA in ETDRS letters, mandatory fields) have formed a highly reliable resource which will be enhanced in the future with an automated update and validation to allow for continued growth and quality improvement of clinical AMD data.
In conclusion, this study shows that with a diligent approach, analysis of well maintained EMR data can lead to high quality real-life results and electronic availability of data facilitates maximisation of its potential in sharing research resources with the community, ultimately with the goal of improving patient care in real-life. In the near future, we plan to report on long-term visual outcomes (e.g., after 5-years), anatomic outcomes, and fellow-eye involvement, as well as the differential therapeutic effects of ranibizumab and aflibercept. In each case, we plan to release the raw data that underpins these reports -we hope that this will help promote an open-science approach to the study of neovascular AMD, and thus to direct patient benefit in the longer term.
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